Halozyme Therapeutics (HALO) Is Up 7.4% After New ENHANZE NSCLC Win And Patent Injunction - What's Changed [Yahoo! Finance]
Halozyme Therapeutics, Inc. (HALO)
Last halozyme therapeutics, inc. earnings: 2/24 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
halozyme.com/investors/default.aspx
Company Research
Source: Yahoo! Finance
non-small cell lung cancer, alongside a preliminary injunction from a German court protecting its patents against a rival product. Together, the new ENHANZE-based approval and the supportive German patent ruling highlight how Halozyme can both extend its technology into new cancer indications and defend the royalty stream underpinning its business model. We'll now examine how this fresh ENHANZE-based approval shapes Halozyme's investment narrative, especially around royalty durability and legal risk. The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. To own Halozyme, you need to believe its ENHANZE drug delivery platform can keep attracting high-value partnerships and durable royalties, despite legal and reimbursement pressures. The RYBREVANT FASPRO approval and German injunction support the near term royalty durability story, but they do not eliminate the broader concen
Show less
Read more
Impact Snapshot
Event Time:
HALO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HALO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HALO alerts
High impacting Halozyme Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HALO
News
- Halozyme Therapeutics (HALO): Valuation Check After FDA Win and Patent Court Victory [Yahoo! Finance]Yahoo! Finance
- Is Halozyme Still Attractively Priced After Its Strong 2025 Share Price Rally? [Yahoo! Finance]Yahoo! Finance
- Huonslab Announces Submission of Biologics License Application for Recombinant Human Hyaluronidase ‘HYDIZYME™' [Yahoo! Finance]Yahoo! Finance
- Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.MarketBeat
- U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung CancerPR Newswire
HALO
Earnings
- 11/3/25 - Beat
HALO
Sec Filings
- 12/19/25 - Form 4
- 12/11/25 - Form 4
- 12/9/25 - Form 8-K
- HALO's page on the SEC website